Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Abstract

Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger. (Funded by the National Cancer Institute and others; TAILORx ClinicalTrials.gov number, NCT00310180 .).

Keywords

Affiliated Institutions

• Northwestern University PH
• University of Hawaiʻi at Mānoa US
• Instituto Nacional de Enfermedades Neoplásicas PE
• Mayo Clinic in Florida US
• National Cancer Institute US
• Virginia Commonwealth University US
• Indiana University – Purdue University Indianapolis US
• Emory University US
• NSABP Foundation US
• Fox Valley Technical College US
• University of North Carolina at Chapel Hill US
• Rutgers Cancer Institute
• National Institutes of Health US
• Cancer Center of Hawaii US
• Jacksonville College US
• Vince Lombardi Cancer Clinic US
• Cancer Trials Ireland IE
• University of Pittsburgh US
• Indiana University School of Medicine
• Duke Medical Center US
• Sunnybrook Research Institute
• University of Hawaii Cancer Center
• University of Michigan US
• Montefiore Medical Center US
• Dana-Farber Cancer Institute US
• Albert Einstein College of Medicine US
• Vanderbilt University US
• Cancer Center of Kansas US
• Sunnybrook Hospital CA
• McMaster University CA
• The University of Texas at San Antonio US
• Rutgers, The State University of New Jersey US
• Washington University in St. Louis US
• University of Hawaii System US
• WinnMed US
• Loyola University Chicago US
• Indiana University Hospital US

Related Publications